JP2015523332A - 経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子 - Google Patents

経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子 Download PDF

Info

Publication number
JP2015523332A
JP2015523332A JP2015512144A JP2015512144A JP2015523332A JP 2015523332 A JP2015523332 A JP 2015523332A JP 2015512144 A JP2015512144 A JP 2015512144A JP 2015512144 A JP2015512144 A JP 2015512144A JP 2015523332 A JP2015523332 A JP 2015523332A
Authority
JP
Japan
Prior art keywords
nanoparticles
peptide
exendin
metabolic
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512144A
Other languages
English (en)
Japanese (ja)
Inventor
ショーン、マシュー、クリーブランド
マーク、アンドリュー、パウリク
ステファン、サロモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2015523332A publication Critical patent/JP2015523332A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015512144A 2012-05-16 2013-05-16 経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子 Pending JP2015523332A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647633P 2012-05-16 2012-05-16
US61/647,633 2012-05-16
PCT/IB2013/000964 WO2013171570A1 (en) 2012-05-16 2013-05-16 Polypeptide loaded poca nanoparticles for oral administration

Publications (1)

Publication Number Publication Date
JP2015523332A true JP2015523332A (ja) 2015-08-13

Family

ID=48577784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512144A Pending JP2015523332A (ja) 2012-05-16 2013-05-16 経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子

Country Status (10)

Country Link
US (1) US20150342897A1 (https=)
EP (1) EP2849775A1 (https=)
JP (1) JP2015523332A (https=)
KR (1) KR20150010953A (https=)
CN (1) CN104411321A (https=)
AU (1) AU2013261214A1 (https=)
CA (1) CA2873536A1 (https=)
IN (1) IN2014DN09297A (https=)
RU (1) RU2014150850A (https=)
WO (1) WO2013171570A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104799440B (zh) * 2014-01-23 2016-06-08 香港纺织及成衣研发中心有限公司 改善代谢综合症的功能服及其制造方法
CN105342999A (zh) * 2014-08-18 2016-02-24 山东绿叶制药有限公司 艾塞那肽口服纳米粒
CN109675020B (zh) * 2019-01-11 2021-05-04 浙江大学 一种口服glp-1多肽类纳米制剂及其制备方法和应用
MX2023006163A (es) 2020-12-18 2023-06-08 Spectrum Brands Inc Herramienta de cepillado para animales y metodos.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
MXPA00004670A (es) 1997-11-14 2003-07-14 Amylin Pharmaceuticals Inc Compuestos agonistas de exendina novedosos.
EP1054594B1 (en) 1998-02-13 2007-07-04 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
BR122019021416A2 (https=) 2003-09-19 2019-12-21
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
CN102016814B (zh) 2005-06-17 2013-10-23 北卡罗来纳大学查珀尔希尔分校 纳米粒子制备方法、系统及材料
US20080138418A1 (en) * 2006-12-07 2008-06-12 Tong Shen Enterprise Co., Ltd. Nanoparticles composed of alkyl-cyanoacrylate polymers
EP2207670B1 (en) 2007-10-12 2019-05-22 Liquidia Technologies, Inc. Method for producing particles and patterned films

Also Published As

Publication number Publication date
KR20150010953A (ko) 2015-01-29
WO2013171570A1 (en) 2013-11-21
CA2873536A1 (en) 2013-11-21
US20150342897A1 (en) 2015-12-03
RU2014150850A (ru) 2016-07-10
AU2013261214A1 (en) 2014-11-20
EP2849775A1 (en) 2015-03-25
IN2014DN09297A (https=) 2015-07-10
CN104411321A (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
Verma et al. Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability
Vargason et al. The evolution of commercial drug delivery technologies
Gedawy et al. Oral insulin delivery: existing barriers and current counter-strategies
Song et al. Synthesis of CSK-DEX-PLGA nanoparticles for the oral delivery of exenatide to improve its mucus penetration and intestinal absorption
Seo et al. Sustained release of exendin 4 using injectable and ionic-nano-complex forming polymer hydrogel system for long-term treatment of type 2 diabetes mellitus
Soudry-Kochavi et al. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach
Momoh et al. Microemulsion-based approach for oral delivery of insulin: formulation design and characterization
EP3099293B1 (en) Nanoencapsulation of hydrophilic active compounds
US10583080B2 (en) Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN110662550A (zh) 生理活性物质的口服给药
JP2015523332A (ja) 経口投与のためのポリペプチド搭載ｐｏｃａナノ粒子
Pinto et al. Bioengineered nanomedicines targeting the intestinal fc receptor achieve the improved glucoregulatory effect of semaglutide in a type 2 diabetic mice model
Lee Glucagon‐Like Peptide‐1 Formulation–the Present and Future Development in Diabetes Treatment
Li et al. Distribution, transition, adhesion and release of insulin loaded nanoparticles in the gut of rats
CN117545509A (zh) 寡核苷酸的口服递送
CN110623944B (zh) 一种胰高血糖素样肽-1类似物缓释微球制剂及其制备方法
US20210038697A1 (en) Virus-like nanocapsid for oral delivery of insulin
CN102657871A (zh) 一种口服缓释制剂、包载材料及制备方法
Son et al. Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects
M Ramesan et al. Recent advances in the oral delivery of insulin
Raval et al. Nanotechnology Enabled Advances in Oral Delivery of Therapeutic Peptides: Mechanistic Insights for Translation to Clinic
Parida et al. Overcoming hurdles in oral protein and peptide drug delivery: Strategies for future prospective
Raval et al. Nano-biotechnology and its innovative perspective in diabetes management
New Oral delivery of biologics via the intestine. Pharmaceutics. 2021; 13: 18
Zhang Development of Peptide and Protein Microparticles for Diabetes Therapy: From Fabrication to In Vivo Evaluation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150203